MNZO Stock Overview
A specialty pharmaceutical company, engages in the research, development, and testing of patented and non-patented solutions and remedies. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
Manzo Pharmaceuticals, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.000001 |
| 52 Week High | US$0.000001 |
| 52 Week Low | US$0.000001 |
| Beta | 0 |
| 11 Month Change | 0% |
| 3 Month Change | n/a |
| 1 Year Change | 0% |
| 33 Year Change | -99.80% |
| 5 Year Change | -99.00% |
| Change since IPO | -100.00% |
Recent News & Updates
Recent updates
Shareholder Returns
| MNZO | US Pharmaceuticals | US Market | |
|---|---|---|---|
| 7D | 0% | 2.6% | 0.5% |
| 1Y | 0% | 13.1% | 30.7% |
Return vs Industry: MNZO underperformed the US Pharmaceuticals industry which returned 14.2% over the past year.
Return vs Market: MNZO underperformed the US Market which returned 32.3% over the past year.
Price Volatility
| MNZO volatility | |
|---|---|
| MNZO Average Weekly Movement | n/a |
| Pharmaceuticals Industry Average Movement | 9.9% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in US Market | 16.3% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: MNZO's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: Insufficient data to determine MNZO's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1980 | n/a | Kenneth Manzo | www.lactofreedom.com |
Manzo Pharmaceuticals, Inc., a specialty pharmaceutical company, engages in the research, development, and testing of patented and non-patented solutions and remedies. The company is involved in developing Lacto-Freedom, a patented probiotic, which aids in the digestion of lactose containing foods primarily for people with lactose intolerance; and a natural remedy for colic in babies. It was formerly known as Fortune Oil & Gas, Inc. and changed its name to Manzo Pharmaceuticals, Inc. in September 2014.
Manzo Pharmaceuticals, Inc. Fundamentals Summary
| MNZO fundamental statistics | |
|---|---|
| Market cap | US$1.10k |
| Earnings (TTM) | US$7.75m |
| Revenue (TTM) | n/a |
0.0x
P/E Ratio0.0x
P/S RatioIs MNZO overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| MNZO income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$517.23k |
| Gross Profit | -US$517.23k |
| Other Expenses | -US$8.27m |
| Earnings | US$7.75m |
Last Reported Earnings
Sep 30, 2005
Next Earnings Date
n/a
| Earnings per share (EPS) | 0 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0.0% |
How did MNZO perform over the long term?
See historical performance and comparison